Are you a Health Professional? Jump over to the doctors only platform. Click Here

Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial

Print Friendly, PDF & Email

36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic children.

Official Title

The Prolongation of the EPAAC Trial (The Early Prevention of Asthma in Atopic Children). A Multi-Country, Double Blind, Placebo (PLC) Controlled, Follow-up Trial With 3 Parallel Groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : Evaluation of the Long Term Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for an Additional 18 Months Period in Preventing the Onset of Asthma in Children Coming From the EPAAC Trial.


Study Type


Study Design

Randomized, Double-Blind, Placebo Control, Parallel Assignment

Further Details

Primary Outcome Measures: 

  • To assess the effect on the time to onset of asthma of 36-month treatment with Levocetirizine as compare to placebo, in asthma free young atopic children sensitized to Grass Pollen (GP) and/or House Dust Mite allergens (HDM).

    Secondary Outcome Measures:

  • To investigate the clinical benefit on the time to onset of asthma after 36-month of treatment in the LCTZ-LCTZ group as compared to LCTZ-PLC group.
  • To investigate whether the benefit on the time to onset of asthma after 18-month of treatment with LCTZ can be maintained over an additional 18-month period, once active treatment is stopped
  • To investigate the clinical benefit on the time to onset of asthma of an additional 18-month treatment period in the subset of subjects still asthma-free after the first 18-month treatment period.
  • To assess the safety of the long-term use of LCTZ in a large population of children aged between 30 and 60 months.

    Study Start

    June 2004

    Eligibility & Criteria

    Ages Eligible for Study: 30 Months – 42 Months
    Genders Eligible for Study: Both

    Inclusion Criteria:
    Inclusion criteria which must be verified at the end of first 18-months treatment (V9): Having completed the previous 18-month treatment period of the EPAAC trial

    Exclusion Criteria:

    No longer recruiting

    Total Enrolment


    Contact Details

    Parkville (North Melbourne),  Australia
    North Adelaide,  Australia

  • Print Friendly, PDF & Email


    Posted On: 1 January, 2013
    Modified On: 16 September, 2014


    Created by: myVMC